This specialized case study highlights Kymanox’s expert product development support for advanced gene therapy, focusing on intravenous delivery system optimization and risk mitigation. Our team of SMEs collaborated closely with stakeholders to deliver measurable improvements in formulation compatibility, delivery system reliability, and clinical trial readiness to enable safer and more effective therapy administration.
CHALLENGE
SOLUTION
RESULTS
- Develop a safe and effective intravenous delivery method for a novel gene therapy entering early clinical trials.
- Address unforeseen compatibility issues between the gene therapy formulation and polymeric materials used in infusion pumps and tubing sets.
- Ensure delivery system reliability to avoid adverse reactions and maintain therapeutic efficacy.
- Investigated formulation and infusion system compatibility, identifying and mitigating adsorption and container closure integrity challenges.
- Conducted material selection and design verification studies to ensure infusion systems met therapeutic delivery requirements.
- Applied iterative risk analysis to identify potential performance and safety risks, developing a robust control strategy.
- Adapted the Quality Management System (QMS) to cover combination product needs, including delivery system compatibility.
- Optimized formulation and qualified infusion systems successfully delivered the intended dose with minimized side effects, allowing clinical trial progression.
- Developed a trial design mitigating previous compatibility and immune response concerns, supporting safe and reliable gene therapy administration.
- Established best practices for future drug delivery system selections, such as early characterization, proactive risk management, and expert collaboration for complex administration routes.
- Paved the way for future gene therapy trials involving high-risk administration routes with a structured, collaborative development process.